Add to ORKGThe commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. This review considers the safety of pharmacotherapy of osteoporosis in cardiology patients. Drugs used for osteoporosis treatment may have adverse effects on the cardiovascular system. This article has detailed analysed of current drug classes, such as the bisphosphonates and strontium ranelate, as well as reviewed of the controversy surrounding hormone replace-ment therapy (HRT) and the selective estrogen receptor modulators (SERMs). Additionally, we discuss the adverse effects on the heart of calcium and drugs influencing calcium metabolism such as vitamin D, parathormone and calcitonin. We look at the interference between oste-oporosis trea...
The range of osteoporosis treatments is increasingly large and, like any disease, the pharmacologica...
The range of osteoporosis treatments is increasingly large and, like any disease, the pharmacologica...
Summary: We explored the cardiac safety of the osteoporosis treatment strontium ranelate in the UK C...
The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. T...
The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. T...
The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. T...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
ABSTRACT Osteoporosis and cardiovascular (CV) disease share common risk factors and pathophysiology....
The range of osteoporosis treatments is increasingly large and, like any disease, the pharmacologica...
The range of osteoporosis treatments is increasingly large and, like any disease, the pharmacologica...
Summary: We explored the cardiac safety of the osteoporosis treatment strontium ranelate in the UK C...
The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. T...
The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. T...
The commonest medical conditions following menopause are osteoporosis and atherosclerotic disease. T...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
The incidence of osteoporosis and cardiovascular disease increases with age, and there are potential...
ABSTRACT Osteoporosis and cardiovascular (CV) disease share common risk factors and pathophysiology....
The range of osteoporosis treatments is increasingly large and, like any disease, the pharmacologica...
The range of osteoporosis treatments is increasingly large and, like any disease, the pharmacologica...
Summary: We explored the cardiac safety of the osteoporosis treatment strontium ranelate in the UK C...